The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Open accessAbstract
Background: It had been suggested that the antidepressant venlafaxine, which inhibits reuptake of both serotonin and (at higher doses) noradrenaline, may result in better outcomes than treatment with selective serotonin reuptake inhibitors (SSRIs). Aims: To compare remission rates during treatment with SSRIs or venlafaxine. Method: Data from eight comparable randomised, double-blind studies of major depressive disorder were pooled to compare remission rates (Hamilton Rating Scale for Depression score ≤ 7) during treatment with venlafaxine (n=851), SSRIs (fluoxetine, paroxetine, fluvoxamine;n=748) or placebo (four studies;n=446). Results: Remission rates were: venlafaxine, 45% (382/851); SSRIs, 35% (260/748); placebo, 25% (110/446) (P< 0.001; odds ratio for remission is 1.50 (1.3–1.9), favouring venlafaxine v.SSRIs). The difference between venlafaxine and the SSRIs was significant at week 2, whereas the difference between SSRIs and placebo reached significance at week 4. Results were not dependent on any one study or the definition of remission. Conclusions: Remission rates were significantly higher with venlafaxine than with an SSRI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
Thase, M. E. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230043006 · Cited by 515
Self-citationThase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331
Self-citationEvidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302
Six-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299
Practice guideline for major depressive disorder in adults. American Psychiatric Association
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.1 · Cited by 226
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185
Cited by
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationNemeroff, C. B., Heim, C. M., Thase, M. E., Klein, D. N., Rush, A. J., Schatzberg, A. F., Ninan, P. T., McCullough, J. P., Weiss, P. M., Dunner, D. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336126100 · Cited by 829
Self-citationCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Self-citationMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Treatment and prevention of depression
Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002) · Psychological Science in the Public Interest · doi:10.1111/1529-1006.00008 · Cited by 511
Self-citation(2005) · PubMed · Cited by 470
Furey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Alexopoulos, G. S., Reynolds, C. F., Bruce, M. L., Katz, I. R., Raue, P. J., Mulsant, B. H., Oslin, D. W., Ten Have, T., & The PROSPECT Group (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08121779 · Cited by 368
“Randomized acute antidepressant trials have shown that 30%–40% of patients achieve remission (26).”
BackgroundNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., Suppes, T., McElroy, S., Keck, P. E., Denicoff, K. D., et al. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.013045 · Cited by 350
Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., Haynor, D. R., Claypoole, K. H., Wajdik, C., & Roy-Byrne, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.003 · Cited by 318
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Kennedy, S. H., Konarski, J. Z., Segal, Z. V., Lau, M. A., Bieling, P. J., McIntyre, R. S., & Mayberg, H. S. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.778 · Cited by 420
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Self-citationConsensus statement: The evaluation and treatment of people with epilepsy and affective disorders
Barry, J. J., Ettinger, A. B., Friel, P., Gilliam, F. G., Harden, C. L., Hermann, B., Kanner, A. M., Caplan, R., Plioplys, S., Salpekar, J., et al. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2008.04.005 · Cited by 249
Drevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Antidepressant efficacy and side-effect burden: a quick guide for clinicians
Santarsieri, D., & Schwartz, T. (2015) · Drugs in Context · doi:10.7573/dic.212290 · Cited by 224
Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions
Thase, M. E., Entsuah, R., Cantillon, M., & Kornstein, S. G. (2005) · Journal of Women s Health · doi:10.1089/jwh.2005.14.609 · Cited by 201
Self-citationAntidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review
Drevets, W. C., Zarate, C. A., & Furey, M. L. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.031 · Cited by 195
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity
Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.07.006 · Cited by 178
Treatment of depression in children and adolescents
Ryan, N. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67321-7 · Cited by 176
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222514.71390.c1 · Cited by 157
Clinical and Neurobiological Effects of Tianeptine and Paroxetine in Major Depression
Nickel, T., Sonntag, A., Schill, J., Zobel, A. W., Ackl, N., Brunnauer, A., Murck, H., Ising, M., Yassouridis, A., Steiger, A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00008 · Cited by 152
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Residual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Evidence review: efficacy and effectiveness of antidepressant treatment in primary care
Simon, G. E. (2002) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00198-6 · Cited by 132
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1015 · Cited by 129
Montgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Executive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression
Alexopoulos, G. S., Kiosses, D. N., Murphy, C., & Heo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300557 · Cited by 117
Carvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
Preventing Relapse and Recurrence of Depression:A Brief Review of Therapeutic Options
Thase, M. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900015212 · Cited by 93
Self-citationPerahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94
Morimoto, S. S., Wexler, B. E., Liu, J., Hu, W., Seirup, J., & Alexopoulos, G. S. (2014) · Nature Communications · doi:10.1038/ncomms5579 · Cited by 91
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
“There are evidence-using meta-analyses that SNRI’s may possess superior efficacy to SSRIs when remission is used as the outcome variable (Thase et al., 2001).”
MethodBipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Self-citationA systematic review of duloxetine and venlafaxine in major depression, including unpublished data
Schueler, Y. ‐., Koesters, M., Wieseler, B., Grouven, U., Kromp, M., Kerekes, M. F., Kreis, J., Kaiser, T., Becker, T., & Weinmann, S. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01599.x · Cited by 87
Relapse rates with long‐term antidepressant drug therapy: a meta‐analysis
Williams, N., Simpson, A. N., Simpson, K., & Nahas, Z. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1033 · Cited by 74
The pharmacological management of depression
Kupfer, D. J. (2005) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2005.7.3/dkupfer · Cited by 69
Owens, M. J., Krulewicz, S., Simon, J. S., Sheehan, D. V., Thase, M. E., Carpenter, D. J., Plott, S. J., & Nemeroff, C. B. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.47 · Cited by 68
Self-citationSaragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
van der Lem, R., van der Wee, N. J. A., van Veen, T., & Zitman, F. G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000330890 · Cited by 63
Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?
Olver, J. S., Burrows, G. D., & Norman, T. R. (2001) · CNS Drugs · doi:10.2165/00023210-200115120-00004 · Cited by 63
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Trivedi, M. H., Desaiah, D., Ossanna, M. J., Pritchett, Y. L., Brannan, S. K., & Detke, M. J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f41d7e · Cited by 59
Pharmacotherapy to sustain the fully remitted state
Kennedy, S., McIntyre, R., Fallu, A., & Lam, R. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0245 · Cited by 56
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-160 · Cited by 51
Developing an intervention for depressed, chronically medically ill elders: A model from COPD
Alexopoulos, G. S., Raue, P. J., Sirey, J. A., & Arean, P. A. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1925 · Cited by 48
Homan, P., Neumeister, A., Nugent, A. C., Charney, D. S., Drevets, W. C., & Hasler, G. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.25 · Cited by 46
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“While the evidence of efficacy for T3 augmentation to TCAs is well established, data on T3 adjunctive to SSRIs are more scarce.”
ResultInfluentialKirwin, J. L., & Gören, J. L. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.3.396.61600 · Cited by 42
Simon, N. M., Zalta, A. K., Worthington III, J. J., Hoge, E. A., Christian, K. M., Stevens, J. C., & Pollack, M. H. (2006) · Depression and Anxiety · doi:10.1002/da.20184 · Cited by 40
Amsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Shang, Y., Gibbs, M. A., Marek, G. J., Stiger, T., Burstein, A. H., Marek, K., Seibyl, J. P., & Rogers, J. F. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e0017 · Cited by 36
Tian, Y., Du, J., Spagna, A., Mackie, M.-A., Gu, X., Dong, Y., Fan, J., & Wang, K. (2016) · Scientific Reports · doi:10.1038/srep28028 · Cited by 36
Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.008 · Cited by 35
Healy, D. (2006) · Global Pharmaceuticals · doi:10.1215/9780822387916-003 · Cited by 35
Trick, L., Stanley, N., Rigney, U., & Hindmarch, I. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042622 · Cited by 34
Xu, Y., Bai, S. J., Lan, X. H., Qin, B., Huang, T., & Xie, P. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20164806 · Cited by 24
Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder.
Hemels, M. E. H., Vicente, C., Sadri, H., Masson, M. J., & Einarson, T. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003197 · Cited by 23
Sacchetti, E., Frank, E., Siracusano, A., Racagni, G., Vita, A., & Turrina, C. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000074 · Cited by 11
Metadata
- Authors
- Thase, M. E., Entsuah, A. R., & Rudolph, R. L.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2001-03
- Volume
- 178
- Issue
- 3
- Pages
- 234-241
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2099564543
- Cited by
- 801
- References
- 13
- FWCI
- 35.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
